However, when tumors metastasize, dMMR/MSI-H becomes a negative prognostic factor, which may be related to the confounding effect of BRAF mutations: in advanced MSI-H CRC, the BRAF V600E mutation rate reaches up to 20%, suggesting that this prognostic difference may be driven by BRAF mutations rather than MSI itself. Here, BRAF is linked to colorectal carcinoma.